OasisLMS

Access is available: 

• Free for conference attendees.
• For purchase for those that did not attend the conference. 

For questions, email: education@iaslc.org.

The IASLC 2026 Targeted Therapy of Lung Cancer Meeting (TTLC), February 19-21, 2026, brings together leading researchers, clinicians, and industry experts to explore the latest breakthroughs in clinical research and targeted therapies for thoracic malignancies. The conference will feature cutting-edge research, early clinical trial data, and expert-led discussions across a range of molecular targets.

The Targeted Therapies of Lung Cancer meeting is designed to meet the educational needs of researchers and healthcare professionals who diagnose and treat patients with lung cancer and other thoracic malignancies, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists, advanced practice nurses, physician assistants and nurses.

Upon completion of this activity, participants should be able to: 

• Understand the latest breakthroughs in clinical research and targeted therapies for thoracic malignancies.
• Understand data on preclinical and early clinical trials for each of the drugs directed against relevant targets.

• Paul Bunn, MD, Distinguished Professor, Medical Oncology, School of Medicine - CU Anschutz, Denver, CO USA
• Shirish Gadgeel, MD, Division Head for Hematology/Oncology, Associate Director, Patient Experience and Clinical Care, Henry Ford Health, Detroit, MI, USA
• Xiuning Le, MD, PhD, Associate Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
• Karen Reckamp, MD, Director, Medical Oncology; Associate Director, Clinical Research, Cedars-Sinai, Los Angeles, CA, USA

The information presented is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

For assistance with this activity, please email: education@iaslc.org.